CALGARY, May 9 /PRNewswire-FirstCall/ - Stem Cell Therapeutics Corp. ("SCT") announces the results of its 2nd Annual General Meeting held today at the Bow Valley Square Conference Centre.
The following resolutions were approved by the Company's Shareholders: 1. Re-election of the Board of Directors for the ensuing year. a. Joseph Tucker, PhD, President & CEO b. Mark Wayne, LLB, CFA, Chief Financial Officer c. James DeMesa, MD, MBA, President & CEO, Migenix Inc. d. Ian Brown, CA, Independent businessman 2. Approval to reappoint Ernst & Young LLP, Chartered Accountants, as the auditors of the Corporation for the ensuing year and to authorize the board to fix the remuneration to be paid to the auditors. 3. Approval of the existing Stock Option Plan. 4. Approval to ratify the repeal of By-Law No. 1 and replacing it with By-Law No. 2.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient's own stem cells to proliferate in the brain. SCT's core technology, which includes its lead therapeutic product NTx(TM)-265, has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals. SCT plans to develop this fundamental technology further for specific disease treatments such as stroke and potentially Huntington's disease, Alzheimer's disease and other neurodegenerative conditions.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Stem Cell Therapeutics Corp.CONTACT: visit www.stemcellthera.com or contact: Dr. Joseph Tucker, ChiefExecutive Officer, Stem Cell Therapeutics Corp., Phone: (403) 245-5495,info@stemcellthera.com